Oleoylethanolamide (Synonyms: N-Oleoylethanolamide; Oleamide MEA; Oleic acid monoethanolamide)

Name: Oleoylethanolamide
Brand: MedChemExpress
SKU: HY-107542
Rating: 5.0 (3 reviews)

製品番号: HY-107542 純度: 98.19%: Data Sheet SDS COA 取扱説明書
FAQs
Technical Support

Oleoylethanolamide is a high affinity endogenous PPAR-α agonist, which plays an important role in the treatment of obesity and arteriosclerosis.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号 : 111-58-0

容量	価格（税別）	在庫状況	数量

>無料サンプル (0.1 - 0.2 mg)		今すぐ申し込む
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 66	在庫あり	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 66	在庫あり	Estimated Time of Arrival: December 31
Solid
5 mg	$60	在庫あり	Estimated Time of Arrival: December 31
10 mg	$90	在庫あり	Estimated Time of Arrival: December 31
25 mg	$200	在庫あり	Estimated Time of Arrival: December 31
50 mg	$320	在庫あり	Estimated Time of Arrival: December 31
100 mg	$480	在庫あり	Estimated Time of Arrival: December 31
200 mg		お問い合わせ
500 mg		お問い合わせ

or バルクお問い合わせ

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 3 publication(s) in Google Scholar

Other Forms of Oleoylethanolamide:

顧客検証

Bio/Physico-chemical Assay

: Oleoylethanolamide purchased from MedChemExpress. Usage Cited in: Autophagy. 2025 Apr 3. [Abstract]; Quantification of S1P concentrations in C2C12 myotubes treated with 10 μM FCCP for 4 h with/without 50 μM NOE or 5 μM SKI-II pre-treatment (n = 4).

: Oleoylethanolamide purchased from MedChemExpress. Usage Cited in: Autophagy. 2025 Apr 3. [Abstract]; PPARGC1A protein levels in the C2C12 myotubes 48 h after the stimulation of 10 μM FCCP with/without 50 μM NOE (24 h) in the absence or presence of 5 μM S1P (n = 3).

: Oleoylethanolamide purchased from MedChemExpress. Usage Cited in: J Agric Food Chem. 2024 Sep 25;72(38):21052-21064. [Abstract]; The PPARα and FGF21 protein expression levels was detected using Western blot after treatment with OEA (10 μM) for 48 h in PA-treated HepG2 cells.

Endogenous Metabolite アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

Human Endogenous Metabolite Microbial Metabolite

PPAR アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

PPARα PPARβ/δ PPARγ PPAR PPARδ

生物活性
プロトコル
純度とドキュメンテーション
参考文献
カスタマーレビュー

製品説明

Oleoylethanolamide is a high affinity endogenous PPAR-α agonist, which plays an important role in the treatment of obesity and arteriosclerosis.

IC₅₀ & Target^[1]

Human Endogenous Metabolite

PPAR-α

Cellular Effect

Cell Line	Type	Value	Description	References
786-0	GI₅₀	35.4 6 Compound: 4c	Antiproliferative activity against human 786-0 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human 786-0 cells after 48 hrs by sulforhodamine B assay	[PMID: 25510639]
786-0	GI₅₀	35.4 6 Compound: 4c	Antiproliferative activity against human 786-0 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human 786-0 cells after 48 hrs by sulforhodamine B assay	[PMID: 25510639]
786-0	GI₅₀	35.4 6 Compound: 4c	Antiproliferative activity against human 786-0 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human 786-0 cells after 48 hrs by sulforhodamine B assay	[PMID: 25510639]
HEK293	EC₅₀	2.2 3 Compound: OEA	Agonist activity at human GPR119 expressed in HEK293 cells assessed as stimulation of cAMP level measured after 60 mins by HTRF assay Agonist activity at human GPR119 expressed in HEK293 cells assessed as stimulation of cAMP level measured after 60 mins by HTRF assay	[PMID: 27825553]
HEK293	EC₅₀	2.2 3 Compound: OEA	Agonist activity at human GPR119 expressed in HEK293 cells assessed as cAMP accumulation after 60 mins Agonist activity at human GPR119 expressed in HEK293 cells assessed as cAMP accumulation after 60 mins	[PMID: 23357035]
HEK293	EC₅₀	2.2 3 Compound: OEA	Agonist activity at human GPR119 expressed in HEK293 cells assessed as increase in cAMP stimulation measured after 60 mins by TR-FRET assay Agonist activity at human GPR119 expressed in HEK293 cells assessed as increase in cAMP stimulation measured after 60 mins by TR-FRET assay	[PMID: 28408218]
HEK293	EC₅₀	2.2 3 Compound: OEA	Agonist activity at human GPR119 expressed in HEK293 cells assessed as increase in cAMP stimulation measured after 60 mins by TR-FRET assay Agonist activity at human GPR119 expressed in HEK293 cells assessed as increase in cAMP stimulation measured after 60 mins by TR-FRET assay	[PMID: 28408218]
HEK293	EC₅₀	2.2 3 Compound: OEA	Agonist activity at human GPR119 expressed in HEK293 cells assessed as cAMP accumulation after 60 mins Agonist activity at human GPR119 expressed in HEK293 cells assessed as cAMP accumulation after 60 mins	[PMID: 23357035]
HEK293	EC₅₀	2.2 3 Compound: OEA	Agonist activity at human GPR119 expressed in HEK293 cells assessed as stimulation of cAMP level measured after 60 mins by HTRF assay Agonist activity at human GPR119 expressed in HEK293 cells assessed as stimulation of cAMP level measured after 60 mins by HTRF assay	[PMID: 27825553]
HEK293	EC₅₀	3.65 3 Compound: 3b, OEA	Agonist activity at human recombinant TRPV1 expressed in HEK293 cells assessed as increase in intracellular calcium level Agonist activity at human recombinant TRPV1 expressed in HEK293 cells assessed as increase in intracellular calcium level	[PMID: 19361197]
HEK293	EC₅₀	0.89 3 Compound: 2a, OEA	Agonist activity on human recombinant TRPV1-mediated enhancement of intracellular calcium concentration in HEK293 cells Agonist activity on human recombinant TRPV1-mediated enhancement of intracellular calcium concentration in HEK293 cells	[PMID: 16570929]
HEK293	EC₅₀	2200 1 Compound: OEA	Agonist activity at human GPR119 transfected in HEK293 cells assessed as concentration for 50 % cAMP stimulation of oleylethanolamine Agonist activity at human GPR119 transfected in HEK293 cells assessed as concentration for 50 % cAMP stimulation of oleylethanolamine	[PMID: 23374864]
HEK293	EC₅₀	0.89 3 Compound: 2a, OEA	Agonist activity on human recombinant TRPV1-mediated enhancement of intracellular calcium concentration in HEK293 cells Agonist activity on human recombinant TRPV1-mediated enhancement of intracellular calcium concentration in HEK293 cells	[PMID: 16570929]
HEK293	EC₅₀	2.2 3 Compound: OEA	Agonist activity at human GPR119 expressed in HEK293 cells assessed as cAMP accumulation after 60 mins Agonist activity at human GPR119 expressed in HEK293 cells assessed as cAMP accumulation after 60 mins	[PMID: 23357035]
HeLa	EC₅₀	0.12 3 Compound: OEA	Transactivation of human Gal4 fused PPARalpha LBD transfected in human HeLa cells after 7 hrs by dual-luciferase reporter gene assay Transactivation of human Gal4 fused PPARalpha LBD transfected in human HeLa cells after 7 hrs by dual-luciferase reporter gene assay	[PMID: 27622746]
HeLa	EC₅₀	0.12 3 Compound: OEA	Transactivation of human Gal4 fused PPARalpha LBD transfected in human HeLa cells after 7 hrs by dual-luciferase reporter gene assay Transactivation of human Gal4 fused PPARalpha LBD transfected in human HeLa cells after 7 hrs by dual-luciferase reporter gene assay	[PMID: 27622746]
HEK293	EC₅₀	2.2 3 Compound: OEA	Agonist activity at human GPR119 expressed in HEK293 cells assessed as stimulation of cAMP level measured after 60 mins by HTRF assay Agonist activity at human GPR119 expressed in HEK293 cells assessed as stimulation of cAMP level measured after 60 mins by HTRF assay	[PMID: 27825553]
HeLa	EC₅₀	1.1 3 Compound: OEA	Transactivation of human Gal4 fused PPARdelta LBD transfected in human HeLa cells after 7 hrs by dual-luciferase reporter gene assay Transactivation of human Gal4 fused PPARdelta LBD transfected in human HeLa cells after 7 hrs by dual-luciferase reporter gene assay	[PMID: 27622746]
HeLa	EC₅₀	1.1 3 Compound: OEA	Transactivation of human Gal4 fused PPARdelta LBD transfected in human HeLa cells after 7 hrs by dual-luciferase reporter gene assay Transactivation of human Gal4 fused PPARdelta LBD transfected in human HeLa cells after 7 hrs by dual-luciferase reporter gene assay	[PMID: 27622746]
HEK293	EC₅₀	2.2 3 Compound: OEA	Agonist activity at human GPR119 expressed in HEK293 cells assessed as increase in cAMP stimulation measured after 60 mins by TR-FRET assay Agonist activity at human GPR119 expressed in HEK293 cells assessed as increase in cAMP stimulation measured after 60 mins by TR-FRET assay	[PMID: 28408218]
MCF7	EC₅₀	152 1 Compound: OEA	Agonist activity at human PPARalpha transfected in human MCF7 cells after 16 hrs by luciferase reporter gene assay Agonist activity at human PPARalpha transfected in human MCF7 cells after 16 hrs by luciferase reporter gene assay	[PMID: 26226490]
HEK293	EC₅₀	2200 1 Compound: OEA	Agonist activity at human GPR119 transfected in HEK293 cells assessed as concentration for 50 % cAMP stimulation of oleylethanolamine Agonist activity at human GPR119 transfected in HEK293 cells assessed as concentration for 50 % cAMP stimulation of oleylethanolamine	[PMID: 23374864]
MCF7	EC₅₀	152 1 Compound: OEA	Agonist activity at human PPARalpha expressed in MCF7 cells co-transfected CPTI DR1-type RE after 16 hrs by luciferase reporter gene assay Agonist activity at human PPARalpha expressed in MCF7 cells co-transfected CPTI DR1-type RE after 16 hrs by luciferase reporter gene assay	[PMID: 24936232]
MCF7	GI₅₀	25.9 6 Compound: 4c	Antiproliferative activity against human MCF7 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human MCF7 cells after 48 hrs by sulforhodamine B assay	[PMID: 25510639]
MCF7	EC₅₀	152 1 Compound: OEA	Agonist activity at human PPARalpha expressed in MCF7 cells co-transfected CPTI DR1-type RE after 16 hrs by luciferase reporter gene assay Agonist activity at human PPARalpha expressed in MCF7 cells co-transfected CPTI DR1-type RE after 16 hrs by luciferase reporter gene assay	[PMID: 24936232]
HEK293	EC₅₀	3.65 3 Compound: 3b, OEA	Agonist activity at human recombinant TRPV1 expressed in HEK293 cells assessed as increase in intracellular calcium level Agonist activity at human recombinant TRPV1 expressed in HEK293 cells assessed as increase in intracellular calcium level	[PMID: 19361197]
MCF7	EC₅₀	185 1 Compound: OEA	Agonist activity at human PPARalpha expressed in MCF7 cells co-transfected CPTI DR1-type RE after 6 hrs by luciferase reporter gene assay Agonist activity at human PPARalpha expressed in MCF7 cells co-transfected CPTI DR1-type RE after 6 hrs by luciferase reporter gene assay	[PMID: 24936232]
MCF7	EC₅₀	152 1 Compound: OEA	Agonist activity at human PPARalpha transfected in human MCF7 cells after 16 hrs by luciferase reporter gene assay Agonist activity at human PPARalpha transfected in human MCF7 cells after 16 hrs by luciferase reporter gene assay	[PMID: 26226490]
MCF7	GI₅₀	25.9 6 Compound: 4c	Antiproliferative activity against human MCF7 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human MCF7 cells after 48 hrs by sulforhodamine B assay	[PMID: 25510639]
MCF7	EC₅₀	185 1 Compound: OEA	Agonist activity at human PPARalpha expressed in MCF7 cells co-transfected CPTI DR1-type RE after 6 hrs by luciferase reporter gene assay Agonist activity at human PPARalpha expressed in MCF7 cells co-transfected CPTI DR1-type RE after 6 hrs by luciferase reporter gene assay	[PMID: 24936232]
NCI/ADR-RES	GI₅₀	9.1 6 Compound: 4c	Antiproliferative activity against human NCI/ADR-RES cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human NCI/ADR-RES cells after 48 hrs by sulforhodamine B assay	[PMID: 25510639]
NCI-H460	GI₅₀	36.5 6 Compound: 4c	Antiproliferative activity against human NCI-H460 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human NCI-H460 cells after 48 hrs by sulforhodamine B assay	[PMID: 25510639]
NCI/ADR-RES	GI₅₀	9.1 6 Compound: 4c	Antiproliferative activity against human NCI/ADR-RES cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human NCI/ADR-RES cells after 48 hrs by sulforhodamine B assay	[PMID: 25510639]
NCI-H460	GI₅₀	36.5 6 Compound: 4c	Antiproliferative activity against human NCI-H460 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human NCI-H460 cells after 48 hrs by sulforhodamine B assay	[PMID: 25510639]
OVCAR-3	GI₅₀	35.4 6 Compound: 4c	Antiproliferative activity against human OVCAR3 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human OVCAR3 cells after 48 hrs by sulforhodamine B assay	[PMID: 25510639]
OVCAR-3	GI₅₀	35.4 6 Compound: 4c	Antiproliferative activity against human OVCAR3 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human OVCAR3 cells after 48 hrs by sulforhodamine B assay	[PMID: 25510639]
PC-3	GI₅₀	16.9 6 Compound: 4c	Antiproliferative activity against human PC3 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human PC3 cells after 48 hrs by sulforhodamine B assay	[PMID: 25510639]
RBL-2H3	IC₅₀	> 50 3 Compound: 10	Antiallergic activity in rat RBL2H3 cells assessed as inhibition of DNP-HSA-mediated degranulation by measuring decrease in beta-hexosaminidase activity preincubated for 30 mins followed by DNP-HSA stimulation and measured after 30 mins by 4-nitrophenyl 2 Antiallergic activity in rat RBL2H3 cells assessed as inhibition of DNP-HSA-mediated degranulation by measuring decrease in beta-hexosaminidase activity preincubated for 30 mins followed by DNP-HSA stimulation and measured after 30 mins by 4-nitrophenyl 2	[PMID: 31618024]
PC-3	GI₅₀	16.9 6 Compound: 4c	Antiproliferative activity against human PC3 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human PC3 cells after 48 hrs by sulforhodamine B assay	[PMID: 25510639]
RBL-2H3	IC₅₀	>50 3 Compound: 10	Antiallergic activity in rat RBL2H3 cells assessed as inhibition of DNP-HSA-mediated degranulation by measuring decrease in beta-hexosaminidase activity preincubated for 30 mins followed by DNP-HSA stimulation and measured after 30 mins by 4-nitrophenyl 2 Antiallergic activity in rat RBL2H3 cells assessed as inhibition of DNP-HSA-mediated degranulation by measuring decrease in beta-hexosaminidase activity preincubated for 30 mins followed by DNP-HSA stimulation and measured after 30 mins by 4-nitrophenyl 2	[PMID: 31618024]
HeLa	EC₅₀	0.12 3 Compound: OEA	Transactivation of human Gal4 fused PPARalpha LBD transfected in human HeLa cells after 7 hrs by dual-luciferase reporter gene assay Transactivation of human Gal4 fused PPARalpha LBD transfected in human HeLa cells after 7 hrs by dual-luciferase reporter gene assay	[PMID: 27622746]
SK-OV-3	IC₅₀	24 3 Compound: N-oleylethanolamine	Inhibition of ceramidase in human SKOV3 cells assessed as hydrolysis of N-((2S,3R)-1,3-dihydroxy-5-((2-oxo-2H-chromen-7- yl)oxy)pentan-2-yl)palmitamide at 16 uM after 24 hrs at 37 degC by HPLC Inhibition of ceramidase in human SKOV3 cells assessed as hydrolysis of N-((2S,3R)-1,3-dihydroxy-5-((2-oxo-2H-chromen-7- yl)oxy)pentan-2-yl)palmitamide at 16 uM after 24 hrs at 37 degC by HPLC	[PMID: 20085856]
RBL-2H3	IC₅₀	20 3 Compound: 2a, OEA	Inhibition of AEA uptake in RBL2H3 cells Inhibition of AEA uptake in RBL2H3 cells	[PMID: 16570929]
HeLa	EC₅₀	1.1 3 Compound: OEA	Transactivation of human Gal4 fused PPARdelta LBD transfected in human HeLa cells after 7 hrs by dual-luciferase reporter gene assay Transactivation of human Gal4 fused PPARdelta LBD transfected in human HeLa cells after 7 hrs by dual-luciferase reporter gene assay	[PMID: 27622746]
SK-OV-3	IC₅₀	28 3 Compound: N-oleylethanolamine	Inhibition of ceramidase in human SKOV3 cells assessed as hydrolysis of N-((2S,3R)-1,3-dihydroxy-5-((2-oxo-2H-chromen-7- yl)oxy)pentan-2-yl)palmitamide at 16 uM after 24 hrs at 37 degC by umbelliferone formation based fluorescence intensity assay Inhibition of ceramidase in human SKOV3 cells assessed as hydrolysis of N-((2S,3R)-1,3-dihydroxy-5-((2-oxo-2H-chromen-7- yl)oxy)pentan-2-yl)palmitamide at 16 uM after 24 hrs at 37 degC by umbelliferone formation based fluorescence intensity assay	[PMID: 20085856]
HEK293	EC₅₀	2200 1 Compound: OEA	Agonist activity at human GPR119 transfected in HEK293 cells assessed as concentration for 50 % cAMP stimulation of oleylethanolamine Agonist activity at human GPR119 transfected in HEK293 cells assessed as concentration for 50 % cAMP stimulation of oleylethanolamine	[PMID: 23374864]
MCF7	EC₅₀	152 1 Compound: OEA	Agonist activity at human PPARalpha expressed in MCF7 cells co-transfected CPTI DR1-type RE after 16 hrs by luciferase reporter gene assay Agonist activity at human PPARalpha expressed in MCF7 cells co-transfected CPTI DR1-type RE after 16 hrs by luciferase reporter gene assay	[PMID: 24936232]
U-251	GI₅₀	27.3 6 Compound: 4c	Antiproliferative activity against human U251 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human U251 cells after 48 hrs by sulforhodamine B assay	[PMID: 25510639]
SK-OV-3	IC₅₀	24 3 Compound: N-oleylethanolamine	Inhibition of ceramidase in human SKOV3 cells assessed as hydrolysis of N-((2S,3R)-1,3-dihydroxy-5-((2-oxo-2H-chromen-7- yl)oxy)pentan-2-yl)palmitamide at 16 uM after 24 hrs at 37 degC by HPLC Inhibition of ceramidase in human SKOV3 cells assessed as hydrolysis of N-((2S,3R)-1,3-dihydroxy-5-((2-oxo-2H-chromen-7- yl)oxy)pentan-2-yl)palmitamide at 16 uM after 24 hrs at 37 degC by HPLC	[PMID: 20085856]
MCF7	EC₅₀	152 1 Compound: OEA	Agonist activity at human PPARalpha transfected in human MCF7 cells after 16 hrs by luciferase reporter gene assay Agonist activity at human PPARalpha transfected in human MCF7 cells after 16 hrs by luciferase reporter gene assay	[PMID: 26226490]
SK-OV-3	IC₅₀	28 3 Compound: N-oleylethanolamine	Inhibition of ceramidase in human SKOV3 cells assessed as hydrolysis of N-((2S,3R)-1,3-dihydroxy-5-((2-oxo-2H-chromen-7- yl)oxy)pentan-2-yl)palmitamide at 16 uM after 24 hrs at 37 degC by umbelliferone formation based fluorescence intensity assay Inhibition of ceramidase in human SKOV3 cells assessed as hydrolysis of N-((2S,3R)-1,3-dihydroxy-5-((2-oxo-2H-chromen-7- yl)oxy)pentan-2-yl)palmitamide at 16 uM after 24 hrs at 37 degC by umbelliferone formation based fluorescence intensity assay	[PMID: 20085856]
MCF7	EC₅₀	185 1 Compound: OEA	Agonist activity at human PPARalpha expressed in MCF7 cells co-transfected CPTI DR1-type RE after 6 hrs by luciferase reporter gene assay Agonist activity at human PPARalpha expressed in MCF7 cells co-transfected CPTI DR1-type RE after 6 hrs by luciferase reporter gene assay	[PMID: 24936232]
U-251	GI₅₀	27.3 6 Compound: 4c	Antiproliferative activity against human U251 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human U251 cells after 48 hrs by sulforhodamine B assay	[PMID: 25510639]
MCF7	GI₅₀	25.9 6 Compound: 4c	Antiproliferative activity against human MCF7 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human MCF7 cells after 48 hrs by sulforhodamine B assay	[PMID: 25510639]
NCI-H460	GI₅₀	36.5 6 Compound: 4c	Antiproliferative activity against human NCI-H460 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human NCI-H460 cells after 48 hrs by sulforhodamine B assay	[PMID: 25510639]
NCI/ADR-RES	GI₅₀	9.1 6 Compound: 4c	Antiproliferative activity against human NCI/ADR-RES cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human NCI/ADR-RES cells after 48 hrs by sulforhodamine B assay	[PMID: 25510639]
OVCAR-3	GI₅₀	35.4 6 Compound: 4c	Antiproliferative activity against human OVCAR3 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human OVCAR3 cells after 48 hrs by sulforhodamine B assay	[PMID: 25510639]
PC-3	GI₅₀	16.9 6 Compound: 4c	Antiproliferative activity against human PC3 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human PC3 cells after 48 hrs by sulforhodamine B assay	[PMID: 25510639]
RBL-2H3	IC₅₀	20 3 Compound: 2a, OEA	Inhibition of AEA uptake in RBL2H3 cells Inhibition of AEA uptake in RBL2H3 cells	[PMID: 16570929]
RBL-2H3	IC₅₀	> 50 3 Compound: 10	Antiallergic activity in rat RBL2H3 cells assessed as inhibition of DNP-HSA-mediated degranulation by measuring decrease in beta-hexosaminidase activity preincubated for 30 mins followed by DNP-HSA stimulation and measured after 30 mins by 4-nitrophenyl 2 Antiallergic activity in rat RBL2H3 cells assessed as inhibition of DNP-HSA-mediated degranulation by measuring decrease in beta-hexosaminidase activity preincubated for 30 mins followed by DNP-HSA stimulation and measured after 30 mins by 4-nitrophenyl 2	[PMID: 31618024]
SK-OV-3	IC₅₀	24 3 Compound: N-oleylethanolamine	Inhibition of ceramidase in human SKOV3 cells assessed as hydrolysis of N-((2S,3R)-1,3-dihydroxy-5-((2-oxo-2H-chromen-7- yl)oxy)pentan-2-yl)palmitamide at 16 uM after 24 hrs at 37 degC by HPLC Inhibition of ceramidase in human SKOV3 cells assessed as hydrolysis of N-((2S,3R)-1,3-dihydroxy-5-((2-oxo-2H-chromen-7- yl)oxy)pentan-2-yl)palmitamide at 16 uM after 24 hrs at 37 degC by HPLC	[PMID: 20085856]
SK-OV-3	IC₅₀	28 3 Compound: N-oleylethanolamine	Inhibition of ceramidase in human SKOV3 cells assessed as hydrolysis of N-((2S,3R)-1,3-dihydroxy-5-((2-oxo-2H-chromen-7- yl)oxy)pentan-2-yl)palmitamide at 16 uM after 24 hrs at 37 degC by umbelliferone formation based fluorescence intensity assay Inhibition of ceramidase in human SKOV3 cells assessed as hydrolysis of N-((2S,3R)-1,3-dihydroxy-5-((2-oxo-2H-chromen-7- yl)oxy)pentan-2-yl)palmitamide at 16 uM after 24 hrs at 37 degC by umbelliferone formation based fluorescence intensity assay	[PMID: 20085856]
U-251	GI₅₀	27.3 6 Compound: 4c	Antiproliferative activity against human U251 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human U251 cells after 48 hrs by sulforhodamine B assay	[PMID: 25510639]

体外実験

Oleoylethanolamide (OEA), an endogenous PPAR-α ligand, attenuates liver fibrosis targeting hepatic stellate cells. Oleoylethanolamide suppresses TGF-β1 induced hepatic stellate cells (HSCs) activation in vitro via PPAR-α. To assess the impact of Oleoylethanolamide on HSCs activation, the expression levels of α-SMA and Col1a in TGF-β1-stimulated HSCs are examined by qPCR. The mRNA levels of α-SMA and Col1a are markedly induced in the group of CFSC cells with TGF-β1 (5 ng/mL) stimulation for 48h, while the mRNA levels are suppressed when treated with Oleoylethanolamide in a dose-dependent manner. Immunofluorescence and western blot results show that Oleoylethanolamide treatment dose-dependently inhibits the protein expression of α-SMA, the marker of HSC activation. The inhibitory effects of Oleoylethanolamide on HSCs activation are completely blocked by PPAR-α antagonist MK886 (10 μM). Moreover, the mRNA and protein expression levels of PPAR-α are down-regulated with TGF-β1 stimulation, while Oleoylethanolamide treatment restores these changes in dose-dependent manner. In addition, the phosphorylation of Smad 2/3 is upregulated in the presence of TGF-β1 stimulation, consistent with the observed effects on HSC activation, while Oleoylethanolamide (10 μM) reduces the phosphorylation of Smad2/3 in CFSC simulated with TGF-β1^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

Oleoylethanolamide (OEA) can significantly suppress the pro-fibrotic cytokine TGF-β1 negatively regulate genes in the TGF-β1 signaling pathway (α-SMA, collagen 1a, and collagen 3a) in mice models of hepatic fibrosis. Treatment with Oleoylethanolamide (5 mg/kg/day, intraperitoneal injection, i.p.) significantly attenuates the progress of liver fibrosis in both two experimental animal models by blocking the activation of hepatic stellate cells (HSCs)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

臨床実験

分子量

325.53

分子式

C₂₀H₃₉NO₂

CAS 番号

111-58-0

Appearance

Solid

Color

White to light yellow

SMILES

CCCCCCCC/C=C\CCCCCCCC(NCCO)=O

Structure Classification

Others

Initial Source

Microorganisms

輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

溶剤 & 溶解度

体外:

DMSO : 20.83 mg/mL (63.99 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.0719 mL	15.3596 mL	30.7191 mL
5 mM	0.6144 mL	3.0719 mL	6.1438 mL
10 mM	0.3072 mL	1.5360 mL	3.0719 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）

体積 _（開始）

濃度 _（終了）

体積 _（終了）

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (6.39 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (6.39 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

純度とドキュメンテーション

純度: 98.19%

Select Batch:

データシート (272 KB) SDS (393 KB)

COA (238 KB) HNMR (291 KB) RP-HPLC (253 KB) LCMS (93 KB)

取扱説明書 (2659 KB)

参考文献

[1]. Chen L, et al. Oleoylethanolamide, an endogenous PPAR-α ligand, attenuates liver fibrosis targeting hepatic stellate cells. Oncotarget. 2015 Dec 15;6(40):42530-40 [Content Brief]

細胞実験 ^[1]	CFSC, HSC cell lines are first obtained from cirrhotic rat liver, and have a similar phenotype to that of early passage primary HSCs. CFSC cells are cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. All cells are cultured in 6-well culture plates under 37°C and 5% CO₂ in an incubator. The medium is replaced every two days, and the cells are harvested and diluted at a ratio of 1:3 twice a week. In experiments, HSCs are pretreated with the experimental concentration of Oleoylethanolamide (30 μM, 10 μM, 3 μM) before stimulation with 5 ng/mL TGF-β1. mRNA expression levels of α-SMA (A) and Col1a (B) are analyzed by real-time PCR^[1]. MedChemExpress (MCE) はこれらの方法の精度を確認していません。こちらは参照専用です。
動物実験 ^[1]	Mice^[1] The Sv/129 mice and PPAR-α knockout mice are maintained in a room with controlled temperature (21-23°C), humidity (55-60%) and lighting (12 h light/dark cycles) and given water ad libitum. Mice are randomly divided for methionine choline-deficient (MCD) and thioacetamide (TAA) experiments. In the MCD-diet feeding experiment, wild-type Sv/129 mice and PPAR-α knockout mice are each divided into three groups (n=8 /group): (i) control group receive normal diet; (ii) fed with MCD diet and injected with the vehicle (5% Tween-80+5% PEG400+90% saline, 5 mL/kg/day, 8 weeks, intraperitoneal injection, i.p.); (iii) fed with MCD diet along with Oleoylethanolamide administration (5 mg/kg/day; 8 weeks, i.p.). In another set of experiment, all the wild-type mice and PPAR-α knockout mice are given standard chow diet, and are randomly separated into three groups: the control group is not administrated TAA or Oleoylethanolamide but is injected with the saline; the TAA group is injected with TAA (160 mg/kg, three times per week, 6 weeks, dissolved in saline, i.p.) plus the corresponding vehicle; the Oleoylethanolamide group is both injected with TAA and Oleoylethanolamide (5 mg/kg/day; 6 weeks, i.p.)^[1]. MedChemExpress (MCE) はこれらの方法の精度を確認していません。こちらは参照専用です。
参考文献	[1]. Chen L, et al. Oleoylethanolamide, an endogenous PPAR-α ligand, attenuates liver fibrosis targeting hepatic stellate cells. Oncotarget. 2015 Dec 15;6(40):42530-40 [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.0719 mL	15.3596 mL	30.7191 mL	76.7978 mL
	5 mM	0.6144 mL	3.0719 mL	6.1438 mL	15.3596 mL
	10 mM	0.3072 mL	1.5360 mL	3.0719 mL	7.6798 mL
	15 mM	0.2048 mL	1.0240 mL	2.0479 mL	5.1199 mL
	20 mM	0.1536 mL	0.7680 mL	1.5360 mL	3.8399 mL
	25 mM	0.1229 mL	0.6144 mL	1.2288 mL	3.0719 mL
	30 mM	0.1024 mL	0.5120 mL	1.0240 mL	2.5599 mL
	40 mM	0.0768 mL	0.3840 mL	0.7680 mL	1.9199 mL
	50 mM	0.0614 mL	0.3072 mL	0.6144 mL	1.5360 mL
	60 mM	0.0512 mL	0.2560 mL	0.5120 mL	1.2800 mL

Oleoylethanolamide Related Classifications

Metabolic Disease Cardiovascular Disease

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量		濃度		体積		分子量 *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）	×	体積 _（開始）	=	濃度 _（終了）	×	体積 _（終了）
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Oleoylethanolamide111-58-0N-Oleoylethanolamide Oleamide MEA Oleic acid monoethanolamideEndogenous MetabolitePPARPeroxisome proliferator-activated receptorsInhibitorinhibitorinhibit

日本の代理先をお選びくださいナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
製品名			カスタマ需要量 *
お名前 *			タイトル
メールアドレス *			電話番号 *
デパートメント			組纖名 *
市区町村			都道府県
国或いは地域 *
必ず会社名を記載ください。個人への返信は行いません。
備考

製品名			Lot #
お名前 *			メールアドレス *
電話番号 *			部門 *
組纖名 *			国或いは地域 *
備考

Oleoylethanolamide (Synonyms: N-Oleoylethanolamide; Oleamide MEA; Oleic acid monoethanolamide)

カスタマーレビュー

Other Forms of Oleoylethanolamide:

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

Endogenous Metabolite アイソフォーム固有の製品をすべて表示:

PPAR アイソフォーム固有の製品をすべて表示:

生物活性

プロトコル

純度とドキュメンテーション

参考文献

カスタマーレビュー

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Oleoylethanolamide Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

お名前
メール *

	Sorry, but the email address you supplied was invalid.

Oleoylethanolamide (Synonyms: N-Oleoylethanolamide; Oleamide MEA; Oleic acid monoethanolamide)

カスタマーレビュー

Other Forms of Oleoylethanolamide:

Oleoylethanolamide 関連抗体

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

Endogenous Metabolite アイソフォーム固有の製品をすべて表示:

PPAR アイソフォーム固有の製品をすべて表示:

生物活性

プロトコル

純度とドキュメンテーション

参考文献

カスタマーレビュー

Oleoylethanolamide 関連抗体

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Oleoylethanolamide Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

カスタマーレビュー

Request for HNMR Report

Request for HNMR Report